Circularity Healthcare Is Expanding Its Operations to save Severe Diabetics from Amputation with Its Patented Regenerative Solution D'OXYVA with Recovered CO2

Pasadena, California--(Newsfile Corp. - November 1, 2022) - US-based Circularity Healthcare is now expanding its operations to reach millions of people with its advanced drug delivery biotechnology with the help of 18 of the 20 top-ranked US universities. This is a biotech solution that could potentially save the lives of millions of amputees across the world by enhancing their blood flow and nerve activities. D'OXYVA^[1] (deoxyhemoglobin vasodilator) is a novel, clinically validated blood flow and nerve stimulant for people suffering from neuropathy, fibromyalgia and other severe chronic illnesses. The company is in the last phase of its pivotal clinical trial to obtain emergency use authorization from the US Food and Drug Administration (FDA) in the next couple of months. Universities including UCLA, MIT, Yale, Harvard, Drexel, and many others are currently working to collect pivotal clinical trial evidence for diabetic foot ulcer treatment and amputation prevention using this technology. The company has been selling its products in over two dozen countries and is working with some of the largest hospital and home health care systems around the world.

D'OXYVA^[2] uses a non-invasive, fast-acting, and full-body regenerative technology aimed at solving certain health and cosmetic problems, including Chronic Pain, Arthritis, Back Pain, Long Covid, Neuropathy, Fibromyalgia, Diabetes, Burns, Trauma Wounds, Intimate, Athletic Performance, Venous Insufficiency, Varicose Veins, Spider Veins, Peripheral Vascular, Cardiovascular Complications and others.

This pioneering technology consists of an FDA-approved mini CO2 cartridge that uses ultra-purified carbon dioxide. It brings balance (homeostasis) to the body, even for specific challenging comorbidities, through a water-based, gentle spray-on skin solution. Microcirculation and the autonomic nervous system (ANS) are important in a variety of pathological conditions, and D'OXYVA has been shown to promote major micro-vessel structure regrowth (angiogenesis) and ANS improvements, among other major benefits.

"D'OXYVA^[3] is clinically validated to significantly improve microcirculation, which is an effective treatment option for many conditions. The ongoing multi-site pivotal evidence collection for D'OXYVA by world-renowned medical scientists was expanded with a decade-long record of zero adverse event reports," says Norbert Kiss, CEO of Circularity Healthcare.

The company is actively investing in obtaining the required carbon dioxide used in the technology from sources including industrial factories, vehicles, and the atmosphere. The objective is to capture the CO2 from their points of origin and reuse them resulting in a significant reduction in carbon emissions and saving lives.

About

Circularity Healthcare is an emerging global biotech company with proprietary circulatory health and noninvasive drug delivery technologies. The company is planning to go public on one of the US stock exchanges in the near future. It is headquartered in Pasadena, California, United States and was founded in 2011. Circulatory healthcare specializes in pharmaceuticals, drug delivery, medical devices and wellness.

Media Contact:Name: Mark McCarthyEmail: info@doxyva.com^[4]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/142629^[5]

References

1. ^{^} D'OXYVA (www.newsfilecorp.com)
2. ^{^} D'OXYVA (www.newsfilecorp.com)
3. ^{^} D'OXYVA (www.newsfilecorp.com)
4. ^{^} info@doxyva.com (www.newsfilecorp.com)
5. ^{^} https://www.newsfilecorp.com/release/142629 (www.newsfilecorp.com)